Logo image of RARE

ULTRAGENYX PHARMACEUTICAL IN (RARE) Stock Fundamental Analysis

USA - NASDAQ:RARE - US90400D1081 - Common Stock

33.59 USD
+2.41 (+7.73%)
Last: 11/21/2025, 4:58:30 PM
33.59 USD
0 (0%)
After Hours: 11/21/2025, 4:58:30 PM
Fundamental Rating

3

Overall RARE gets a fundamental rating of 3 out of 10. We evaluated RARE against 533 industry peers in the Biotechnology industry. RARE may be in some trouble as it scores bad on both profitability and health. RARE is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RARE has reported negative net income.
RARE had a negative operating cash flow in the past year.
In the past 5 years RARE always reported negative net income.
RARE had a negative operating cash flow in each of the past 5 years.
RARE Yearly Net Income VS EBIT VS OCF VS FCFRARE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

With a Return On Assets value of -48.71%, RARE perfoms like the industry average, outperforming 50.84% of the companies in the same industry.
With a Return On Equity value of -6330.70%, RARE is not doing good in the industry: 83.68% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -48.71%
ROE -6330.7%
ROIC N/A
ROA(3y)-41.44%
ROA(5y)-32.95%
ROE(3y)-214.63%
ROE(5y)-141.85%
ROIC(3y)N/A
ROIC(5y)N/A
RARE Yearly ROA, ROE, ROICRARE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

RARE's Gross Margin of 84.69% is amongst the best of the industry. RARE outperforms 87.43% of its industry peers.
RARE's Gross Margin has been stable in the last couple of years.
RARE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.3%
GM growth 5Y-1.12%
RARE Yearly Profit, Operating, Gross MarginsRARE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K -200K

More info and screens

2

2. Health

2.1 Basic Checks

RARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RARE has been increased compared to 1 year ago.
The number of shares outstanding for RARE has been increased compared to 5 years ago.
Compared to 1 year ago, RARE has an improved debt to assets ratio.
RARE Yearly Shares OutstandingRARE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
RARE Yearly Total Debt VS Total AssetsRARE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

RARE has an Altman-Z score of -4.32. This is a bad value and indicates that RARE is not financially healthy and even has some risk of bankruptcy.
RARE has a Altman-Z score (-4.32) which is in line with its industry peers.
A Debt/Equity ratio of 83.39 is on the high side and indicates that RARE has dependencies on debt financing.
RARE has a worse Debt to Equity ratio (83.39) than 84.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 83.39
Debt/FCF N/A
Altman-Z -4.32
ROIC/WACCN/A
WACC8.34%
RARE Yearly LT Debt VS Equity VS FCFRARE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

A Current Ratio of 1.89 indicates that RARE should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.89, RARE is doing worse than 77.86% of the companies in the same industry.
A Quick Ratio of 1.74 indicates that RARE should not have too much problems paying its short term obligations.
The Quick ratio of RARE (1.74) is worse than 78.61% of its industry peers.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.74
RARE Yearly Current Assets VS Current LiabilitesRARE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

7

3. Growth

3.1 Past

RARE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.19%, which is quite good.
RARE shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.63%.
RARE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 40.13% yearly.
EPS 1Y (TTM)8.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.29%
Revenue 1Y (TTM)20.63%
Revenue growth 3Y16.82%
Revenue growth 5Y40.13%
Sales Q2Q%14.65%

3.2 Future

RARE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.18% yearly.
RARE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 32.44% yearly.
EPS Next Y18.8%
EPS Next 2Y16.29%
EPS Next 3Y23.42%
EPS Next 5Y25.18%
Revenue Next Year20.05%
Revenue Next 2Y21.83%
Revenue Next 3Y29.87%
Revenue Next 5Y32.44%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
RARE Yearly Revenue VS EstimatesRARE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
RARE Yearly EPS VS EstimatesRARE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 -10 15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RARE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RARE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RARE Price Earnings VS Forward Price EarningsRARE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RARE Per share dataRARE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

RARE's earnings are expected to grow with 23.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.29%
EPS Next 3Y23.42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RARE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ULTRAGENYX PHARMACEUTICAL IN

NASDAQ:RARE (11/21/2025, 4:58:30 PM)

After market: 33.59 0 (0%)

33.59

+2.41 (+7.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)02-11 2026-02-11/amc
Inst Owners100.2%
Inst Owner Change0.01%
Ins Owners3.49%
Ins Owner Change-0.71%
Market Cap3.24B
Revenue(TTM)630.60M
Net Income(TTM)-579.83M
Analysts85.19
Price Target85.47 (154.45%)
Short Float %7.79%
Short Ratio4.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.03%
Min EPS beat(2)-43.75%
Max EPS beat(2)11.68%
EPS beat(4)2
Avg EPS beat(4)-8.27%
Min EPS beat(4)-43.75%
Max EPS beat(4)11.68%
EPS beat(8)5
Avg EPS beat(8)-2.83%
EPS beat(12)6
Avg EPS beat(12)-4.05%
EPS beat(16)6
Avg EPS beat(16)-13.56%
Revenue beat(2)1
Avg Revenue beat(2)-2.46%
Min Revenue beat(2)-5.94%
Max Revenue beat(2)1.02%
Revenue beat(4)2
Avg Revenue beat(4)-1.49%
Min Revenue beat(4)-5.94%
Max Revenue beat(4)4.02%
Revenue beat(8)5
Avg Revenue beat(8)1.05%
Revenue beat(12)6
Avg Revenue beat(12)-1.01%
Revenue beat(16)7
Avg Revenue beat(16)-1.78%
PT rev (1m)-0.25%
PT rev (3m)-1.79%
EPS NQ rev (1m)-2.94%
EPS NQ rev (3m)-4.62%
EPS NY rev (1m)-0.15%
EPS NY rev (3m)-3.05%
Revenue NQ rev (1m)1.18%
Revenue NQ rev (3m)0.48%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)0.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.13
P/FCF N/A
P/OCF N/A
P/B 353.43
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.94
EYN/A
EPS(NY)-4.11
Fwd EYN/A
FCF(TTM)-4.84
FCFYN/A
OCF(TTM)-4.62
OCFYN/A
SpS6.54
BVpS0.1
TBVpS-2.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.71%
ROE -6330.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.69%
FCFM N/A
ROA(3y)-41.44%
ROA(5y)-32.95%
ROE(3y)-214.63%
ROE(5y)-141.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.3%
GM growth 5Y-1.12%
F-Score2
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 83.39
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.7%
Cap/Sales 3.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.74
Altman-Z -4.32
F-Score2
WACC8.34%
ROIC/WACCN/A
Cap/Depr(3y)346.02%
Cap/Depr(5y)389.65%
Cap/Sales(3y)18.19%
Cap/Sales(5y)18.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.29%
EPS Next Y18.8%
EPS Next 2Y16.29%
EPS Next 3Y23.42%
EPS Next 5Y25.18%
Revenue 1Y (TTM)20.63%
Revenue growth 3Y16.82%
Revenue growth 5Y40.13%
Sales Q2Q%14.65%
Revenue Next Year20.05%
Revenue Next 2Y21.83%
Revenue Next 3Y29.87%
Revenue Next 5Y32.44%
EBIT growth 1Y-1.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.09%
EBIT Next 3Y27.06%
EBIT Next 5YN/A
FCF growth 1Y15.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.39%
OCF growth 3YN/A
OCF growth 5YN/A

ULTRAGENYX PHARMACEUTICAL IN / RARE FAQ

What is the ChartMill fundamental rating of ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to RARE.


What is the valuation status of ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?

ChartMill assigns a valuation rating of 1 / 10 to ULTRAGENYX PHARMACEUTICAL IN (RARE). This can be considered as Overvalued.


How profitable is ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?

ULTRAGENYX PHARMACEUTICAL IN (RARE) has a profitability rating of 1 / 10.


What is the financial health of ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?

The financial health rating of ULTRAGENYX PHARMACEUTICAL IN (RARE) is 2 / 10.


Can you provide the dividend sustainability for RARE stock?

The dividend rating of ULTRAGENYX PHARMACEUTICAL IN (RARE) is 0 / 10 and the dividend payout ratio is 0%.